



May 07, 2015

Date

Division/Dept.

Care of

Phone

Fax

E-mail

Your letter

Your ref.

The National Stock Exchange of India Ltd
Exchange Plaza, Bandra Kurla Complex
Mumbai 400051

Bombay Stock Exchange Limited
1st floor, Rotunda Building, Dalal Street
Fort, Mumbai 400001

Dear Sir/Madam,

Sub: Announcement of Unaudited Financial Statements as per clause 41 of the Listing Agreement

With reference to the above captioned subject, we are enclosing herewith a copy of the unaudited Financial Statements for the quarter ended March 31, 2015, approved by the Board of Directors of the Company at its meeting held on May 07, 2015 along with copy of Limited Review Report for the said quarter received from M/s. BSR & CO L.L.P., the statutory auditors of the Company.

The Unaudited Financial Statements shall be published in the newspapers within the stipulated time as per the clause 41 of the Listing Agreement.

Kindly acknowledge the receipt.

Thanking you,

Yours faithfully,
For Merck Limited

Vikas R Gupta
General Counsel & Company Secretary

MERCK LIMITED

Regd. Office: Shivsagar Estate 'A', Dr. Annie Besant Road, Worli, Mumbai - 400018

STATEMENT OF UNAUDITED RESULTS FOR THE QUARTER ENDED 31ST MARCH, 2015

CIN No. L99999MH1967PLC013726, email : corpsec@merckgroup.com

(Rs. in Lakhs)

(Rs. in Lakhs)

Particulars	3 months ended 31/03/2015	Preceding 3 months ended 31/12/2014	Corresponding 3 months ended 31/03/2014 in the previous year	Previous year ended 31/12/2014
	Unaudited	Audited	Unaudited	Audited
1. Income from operations				
a) Net Sales/Income from operations (Net of excise duty)	18,970.80	19,834.04	18,715.20	83,244.84
b) Other operating income	905.18	1,572.97	656.17	3,504.27
Total income from operations (net)	19,875.98	21,407.01	19,371.37	86,749.11
2. Expenses				
a) Cost of materials consumed	5,887.63	4,477.25	7,020.24	26,631.74
b) Purchases of stock-in-trade	3,191.59	4,080.30	4,054.38	15,017.87
c) Changes in inventories of finished goods, work-in-progress and stock in trade	(490.01)	1,432.31	(2,469.13)	(1,602.85)
d) Employee benefits expense	3,047.37	2,886.76	2,683.62	11,356.39
e) Depreciation and amortisation expense	443.31	355.70	310.45	1,268.32
f) Other expenses	6,945.48	8,488.35	7,670.66	29,454.91
Total expenses	19,025.37	21,720.67	19,270.22	82,126.38
3. Profit from operations before other income, finance costs and exceptional items (1-2)	850.61	(312.76)	101.15	4,622.73
4. Other Income	494.11	550.06	500.85	2,033.41
5. Profit from ordinary activities before finance costs and exceptional items (3+4)	1,344.72	237.30	602.00	6,656.14
6. Finance Cost	-	-	-	-
7. Profit from ordinary activities after finance costs but before exceptional items (5-6)	1,344.72	237.30	602.00	6,656.14
8. Exceptional items	-	-	-	-
9. Profit from ordinary activities before tax (7+8)	1,344.72	237.30	602.00	6,656.14
10. Tax expense *	382.78	128.75	246.32	2,333.72
11. Net Profit from ordinary activities after tax (9-10)	961.94	108.55	355.68	4,322.42
12. Extraordinary items (net of tax expense)	-	-	-	-
13. Net Profit for the period (11+12)	961.94	108.55	355.68	4,322.42
14. Paid-up equity share capital (Face Value Rs 10/-)	1,659.94	1,659.94	1,659.94	1,659.94
15. Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	53,770.38
16.i Earnings per share (before extraordinary items) (of Rs 10/- each) (not annualised):				
(a) Basic	5.80	0.65	2.14	26.04
(b) Diluted	5.80	0.65	2.14	26.04
16.ii Earnings per share (after extraordinary items) (of Rs 10/- each) (not annualised):				
(a) Basic	5.80	0.65	2.14	26.04
(b) Diluted	5.80	0.65	2.14	26.04
A PARTICULARS OF SHAREHOLDING				
1 Public shareholding				
- Number of shares	8,000,158	8,000,158	8,000,158	8,000,158
- Percentage of shareholding	48.2	48.2	48.2	48.2
2 Promoters and Promoter Group Shareholding				
(a) Pledged/ Encumbered				
- Number of shares	-	-	-	-
- Percentage of shares (as a % of the total shareholding of Promoter and Promoter group)	-	-	-	-
- Percentage of Shares (as a % of the total share capital of the company)	-	-	-	-
(b) Non-encumbered				
- Number of shares	8,599,224	8,599,224	8,599,224	8,599,224
- Percentage of shares (as a % of the total shareholding of Promoter and Promoter group)	100	100	100	100
- Percentage of shares (as a % of the total share capital of the company)	51.8	51.8	51.8	51.8
* Tax expense consists of:				
Current Tax	538.00	220.00	470.00	2,660.00
Deferred Tax	(155.22)	(91.25)	(223.68)	(326.28)

Segment Wise Revenue, Result and Capital Employed				
Particulars	3 months ended 31/03/2015	Preceding 3 months ended 31/12/2014	Corresponding 3 months ended 31/03/2014 in the previous year	Previous year ended 31/12/2014
	Unaudited	Audited	Unaudited	Audited
1. Segment Revenue				
a) Pharmaceuticals	13,773.79	14,405.66	12,341.04	58,514.09
b) Chemicals	7,347.48	7,002.25	7,498.74	29,480.32
Total	21,121.27	21,407.91	19,839.78	87,994.41
Less : Inter segment revenue	1,245.29	-	468.41	1,245.30
Net Sales and Other Operating Income	19,875.98	21,407.91	19,371.37	86,749.11
2. Segment Results (Profit before Tax and interest from each segment)				
a) Pharmaceuticals	475.05	(933.94)	(587.26)	2,674.77
b) Chemicals	326.44	(733.03)	769.04	2,497.78
Total	801.49	(1,666.97)	181.78	5,172.55
Less :				
Other un-allocable expenditure net off un-allocable Income	(543.23)	(1,904.27)	(420.22)	(1,483.59)
Total Profit before Tax	1,344.72	237.30	602.00	6,656.14
3. Capital Employed				
a) Pharmaceuticals	15,311.60	14,710.72	11,375.90	14,710.72
b) Chemicals	18,320.48	18,319.20	17,526.24	18,319.20
c) Unallocated	22,627.46	22,400.40	23,756.54	22,400.40
Total	56,259.54	55,430.32	52,658.68	55,430.32

Particulars		3 months ended 31/03/2015	
B INVESTOR COMPLAINTS			
Pending at the beginning of the quarter		Nil	
Received during the quarter		Nil	
Disposed of during the quarter		Nil	
Remaining unresolved at the end of the quarter		Nil	

Notes :-

- The above results have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at its meeting held on 7th May 2015. The above results were subjected to a "Limited Review" by the Statutory Auditors.
- Figures for the previous quarter/period have been re-grouped/re-arranged wherever necessary.
- The Company has adopted the useful lives of various fixed assets as specified in Schedule II to the Companies Act, 2013, with effect from 1 January 2015, as against the useful lives adopted earlier as specified in Schedule XIV to the Companies Act, 1956. Accordingly, the depreciation charge for the quarter is higher by Rs. 72.97 lakhs and in respect of assets where the remaining useful life as per Schedule II is Nil as on 1 January 2015, an amount of Rs. 201.05 lakhs is recognized in the opening balance of general reserves.
- The figures of preceeding 3 months ended December 31, 2014 are the balancing figures between audited figures in respect of full previous financial year and the published year to date figures upto the third quarter of the previous financial year. Also, the figures upto the end of the third quarter had only been reviewed and not subjected to audit.

 Place : Mumbai
 Date : 7th May 2015
 Please visit us at our website www.merck.co.in


For Merck Limited

 Anand Nambar
 MANAGING DIRECTOR

BSR & Co. LLP

Chartered Accountants

1st Floor, Lodha Excelus,
Apollo Mills Compound
N. M. Joshi Marg, Mahalaxmi
Mumbai - 400 011
India

Telephone +91 (22) 3989 6000
Fax +91 (22) 3090 2511

Review Report

To the Board of Directors of Merck Limited

We have reviewed the accompanying statement of un-audited financial results ('the Statement') of Merck Limited ('the Company') for the quarter ended 31 March 2015, attached herewith, being submitted by the Company pursuant to the requirement of clause 41 of the listing agreement, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors in their meeting held on 7 May 2015. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the Accounting Standards specified under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For BSR & Co. LLP
Chartered Accountants

Firm's Registration No: 101248W/W-100022



Vikas R Kasat
Partner

Membership No: 105317

Mumbai
7 May 2015

BSR & Co. (a partnership firm with
Registration No. BA61223) converted into
BSR & Co. LLP (a Limited Liability Partnership
with LLP Registration No. AAB-8181)
with effect from October 14, 2013

Registered Office
1st Floor, Lodha Excelus
Apollo Mills Compound
N. M. Joshi Marg, Mahalaxmi
Mumbai - 400 011